Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 1/20 | 0.32 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.32 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.32 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.32 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 2/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22590969 | 1.00 | ULK1 (0.32) | ULK1ULK2MKNK2STK17ASLC22A2 | |
| SCHEMBL21220075 | 1.00 | ULK1 (0.32) | ULK1ULK2MKNK2STK17ASLC22A2 | |
| SCHEMBL19784058 | 0.93 | KMT2A (0.33) | ULK1ULK2MKNK2STK17ASLC22A2 | |
| SCHEMBL19784196 | 0.93 | KMT2A (0.33) | ULK1ULK2MKNK2STK17ASLC22A2 | |
| SCHEMBL22590995 | 0.93 | KMT2A (0.33) | ULK1ULK2MKNK2STK17ASLC22A2 | |
| SCHEMBL19784185 | 0.89 | TRPV1 (0.34) | JAK2P2RX7 | |
| SCHEMBL21220052 | 0.89 | TRPV1 (0.34) | JAK2P2RX7 | |
| SCHEMBL19784069 | 0.89 | ALDH1A1 (0.31) | JAK2GRM4 | |
| SCHEMBL21220081 | 0.89 | ALDH1A1 (0.31) | JAK2GRM4 | |
| SCHEMBL20531919 | 0.89 | SLC22A2 (0.32) | ULK1ULK2MKNK2STK17ASLC22A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190241562-A1 | 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-08-08 | — | — | US | disclosed |
| US-20190241562-A1 | 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-08-08 | — | — | US | disclosed |
| WO-2018011017-A1 | 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241562-A1 | 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | GLS, TNNI3, AADAC | ULK1 2161/4885ULK2 1955/4885MKNK2 2544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.